First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment: the RAAFT-3 Trial
Enrolling By Invitation
99 years or below
All
10 participants needed
1 Location
Brief description of study
To determine if catheter-based atrial fibrillation (AF) ablation is superior to treatment with antiarrhythmic drugs as a first-line therapy for symptomatic persistent AF
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Atrial Fibrillation, afib
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 829475
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
